Antigen reports positive cancer study results
Antigen Express, the Worcester-based subsidiary of Toronto’s Generex Biotechnology Corp., said a Phase II clinical trial of a cancer vaccine corroborates earlier tests.
The company said the AE37 vaccine was effective at preventing a relapse in nearly 300 patients who’ve previously had breast cancer, matching the findings from an October 2011 interim analysis. Those in high-risk groups and ineligible to receive the drug Herceptin benefitted most from the vaccine, the company said.
The company plans to present the full results at the American Society of Clinical Oncology meeting in Chicago from May 30 to June 3.
“We look forward to sharing details of the latest results from this significant study with the medical community and the pharmaceuticals industry,” Mark Fletcher, Generex’s president and CEO, said in a statement.
Antigen has been given permission by the Food and Drug Administration to submit a Phase III study protocol for testing this vaccine on breast cancer patients.
The company has also completed a Phase I trial of the drug for patients with prostate cancer, and is considering trials of AE37 for patients with ovarian, colon and lung cancer.
WBJ Web Partners
Most Recent
Most Recent
0 Comments